Janux Therapeutics Inc (JANX) - Total Liabilities
Based on the latest financial reports, Janux Therapeutics Inc (JANX) has total liabilities worth $86.69 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Janux Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Janux Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Janux Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Janux Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Janux Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Precision Wires India Limited
NSE:PRECWIRE
|
India | Rs9.17 Billion |
|
Taihe Technologies
SHE:300801
|
China | CN¥546.18 Million |
|
Navigator Global Investments Ltd
AU:NGI
|
Australia | AU$164.23 Million |
|
Pan-International Industrial Corp
TW:2328
|
Taiwan | NT$6.81 Billion |
|
Ningbo Peace Bird Fashion
SHG:603877
|
China | CN¥3.29 Billion |
|
Shanxi Guoxin Energy Co Ltd A
SHG:600617
|
China | CN¥20.60 Billion |
|
Suzhou Medsys Tech Co Ltd
SHG:603990
|
China | CN¥404.57 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Janux Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Janux Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Janux Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Janux Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Janux Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $50.70 Million | +30.89% |
| 2024-12-31 | $38.73 Million | +7.42% |
| 2023-12-31 | $36.06 Million | -16.67% |
| 2022-12-31 | $43.27 Million | +220.59% |
| 2021-12-31 | $13.50 Million | -56.26% |
| 2020-12-31 | $30.86 Million | +257.82% |
| 2019-12-31 | $8.62 Million | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more